ClinicalTrials.gg
CompletedNCT00777556Updated Oct 18, 2012Results posted

Emergency Contraception Actual Use Study

A Phase 3 interventional study of DR-104 in Emergency Contraception, sponsored by Duramed Research. Completed at 5 sites in United States. Open to female participants aged 11 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-18.

Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
343
Allocation
Not applicable
Ages
11 Years to 16 Years
Sex
Female
01

Study summary

This is a non-comparative case series study to assess the ability of females 11-16 years of age, inclusive, who are requesting emergency contraception (EC) to use the study product, DR-104 (Plan B® 1.5), appropriately and safely without provider counseling.

Read the detailed description

To simulate an over-the-counter (OTC) setting, each potential subject was expected to read the label text on the outside of the study package and determine whether and how to use the study product without provider direction or assistance. The study product, Plan B® 1.5, was to be dispensed only to those subjects who appropriately self-selected and indicated that they wanted to participate in the study and receive study product. Subjects could also appropriately self-select not to use the study product.

Follow-up contact was to be conducted at approximately one, four, and eight weeks following the date the subject was dispensed study product. At these contacts, subjects answered questions regarding product use, health problems since last contact, and pregnancy status. Subjects were not to be permitted to enroll more than once in this Actual Use Study, however to assess repeat use of emergency contraceptives (EC) (use in addition to the study product) subjects were also queried at the one-, four-, and eight-week follow-up contacts regarding use of additional EC.

02

Conditions studied

  • Emergency Contraception
03

In context

Lead sponsor

Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.

First submitted before Duramed Research became part of Teva Pharmaceutical Industries, Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 16 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Female and 11-16 years of age, inclusive
  • Subject must be requesting emergency for her own use (not for use by another person) and for current (not future) use
  • Subject can read and understand English, according to her own judgment
  • Others as dictated by FDA-approved protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
343 participants (actual)

Study arms

  • Experimental
    DR-104

    One tablet for emergency contraception

    Drug: DR-104

Interventions

  • DrugDR-104

    One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.

    Also known as: Plan B® 1.5, Plan B One-Step®, levonorgestrel

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions

    The percentage of participants who appropriately self-selected Plan B® 1.5 at the Screening/Enrollment Visit after reading the product label. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-diagnose the condition and that treatment with the product is appropriate for them.

    Time frame: Day 1

  2. Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions

    The percentage of participants who having appropriately self-selected and been dispensed Plan B® 1.5, correctly used it according to product labeling. Correct use was considered to have occurred if participants reported at the Week 1 follow-up contact that she took Plan B® 1.5 within 72 hours following unprotected sexual intercourse. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-treat with the product according to the product instructions.

    Time frame: Week 1

Secondary outcomes

  1. Participants With Treatment-Emergent Adverse Events (TEAE)

    Treatment-emergent adverse events included adverse events reported during the protocol-specified following up contacts at weeks 1, 4 and 8 or at any other participant contact for participants who took study drug.

    Time frame: Day 1 to week 8

  2. Participants Summarized by Repeat Use of Emergency Contraception (EC)

    As each participant dispensed Plan B® 1.5 was only given one tablet, repeat use of emergency contraception (EC) indicates use of an EC product other than the study product. Categories reflect the number of repeat uses.

    Time frame: up to week 8

07

Results

Posted Oct 18, 2012

Participant flow

Participant flow — Overall Study
MilestoneDR-104
Started343
Dispensed product307
Safety population299
Used product297
Completed277
Not completed66
Withdrew: Inappropriate self-selection34
Withdrew: Dispensed but did not use product12
Withdrew: Did not complete all 3 follow-up visits20

Outcome measures

PrimaryPercentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions

The percentage of participants who appropriately self-selected Plan B® 1.5 at the Screening/Enrollment Visit after reading the product label. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-diagnose the condition and that treatment with the product is appropriate for them.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions
percentage of participantsDR-104
Percentage of Participants Who Appropriately Self-selected DR-104 (Plan B® 1.5) When Dispensed Under Simulated Over-the-counter (OTC) Conditions90.1 (NA to 86.4)
PrimaryPercentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions

The percentage of participants who having appropriately self-selected and been dispensed Plan B® 1.5, correctly used it according to product labeling. Correct use was considered to have occurred if participants reported at the Week 1 follow-up contact that she took Plan B® 1.5 within 72 hours following unprotected sexual intercourse. Following the standard norms for a therapy to over-the-counter (Rx-to-OTC) switch process, this outcome is an evaluation of potential consumers' ability to self-treat with the product according to the product instructions.

Time frame:
Week 1
Reported as:
Number · percentage of treated participants
Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions
percentage of treated participantsDR-104
Percentage of Participants Who Correctly Used DR-104 When Dispensed Under Simulated OTC Conditions88.6 (NA to 84.4)
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAE)

Treatment-emergent adverse events included adverse events reported during the protocol-specified following up contacts at weeks 1, 4 and 8 or at any other participant contact for participants who took study drug.

Time frame:
Day 1 to week 8
Reported as:
Number · participants
Participants With Treatment-Emergent Adverse Events (TEAE)
participantsDR-104
At least one TEAE43
Withdrawn from study due to an AE0
At least one SAE1
SecondaryParticipants Summarized by Repeat Use of Emergency Contraception (EC)

As each participant dispensed Plan B® 1.5 was only given one tablet, repeat use of emergency contraception (EC) indicates use of an EC product other than the study product. Categories reflect the number of repeat uses.

Time frame:
up to week 8
Reported as:
Number · participants
Participants Summarized by Repeat Use of Emergency Contraception (EC)
participantsDR-104
Repeat uses: 0251
Repeat uses: 138
Repeat uses: 216
Repeat uses: 32

Adverse events

Collected over Day 1 to week 8. Unresolved AEs and pregnancies were followed until resolved.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DR-104—1/299 (0.3%)0/299 (0%)
Most frequent serious events
Most frequent serious events
EventDR-104
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/299

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DR-104
<=18 years343
Between 18 and 65 years0
>=65 years0
Age, Customized
Age, Customized(participants)DR-104
11-13 years old3
14 years old35
15 years old100
16 years old140
17 years old65
Sex: Female, Male
Sex: Female, Male(Participants)DR-104
Female343
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)DR-104
Latina147
African-American48
Multiracial23
White39
Asian/Pacific Islander68
Native American/Alaskan Native1
Other17
Ethnic Latina/Hispanic
Ethnic Latina/Hispanic(participants)DR-104
No answer17
Yes169
No151
Don't know6
08

Study locations

5 sites
  • Duramed Research Investigational Site
    San Francisco, California 94110, United States
  • Duramed Research Investigational Site
    Atlanta, Georgia 30303, United States
  • Duramed Research Investigational Site
    Minneapolis, Minnesota 55404, United States
  • Duramed Research Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Teva Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2008
First posted
Oct 22, 2008
Start
Oct 2008
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Oct 18, 2012
Last update
Oct 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00777556
Lead sponsor
Duramed Research
Responsible party
Sponsor
First posted
Oct 22, 2008
Start date
Oct 2008
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Oct 18, 2012
Last update
Oct 18, 2012

Study contacts

Duramed Research Protocol Chair
study chair · Duramed Research, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion